Advertisement


Nagla Abdel Karim, MD, on Small Cell Lung Cancer: SWOG S1929 Results on Atezolizumab Plus Talazoparib

2023 ASCO Annual Meeting

Advertisement

Nagla Abdel Karim, MD, of the Inova Schar Cancer Institute, University of Virginia, discusses phase II data showing that maintenance atezolizumab plus talazoparib improved progression-free survival in Schlafen-11–selected patients with extensive-stage small cell lung cancer. This study demonstrated the feasibility of conducting biomarker-selected trials in this disease, paving the way for future evaluation of novel therapies in selected populations (Abstract 8504).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Small cell lung cancer is the most aggressive cancer amongst all types of lung cancer. We basically need to find better novel therapies, in addition to finding predictive biomarkers to select the best therapy for the appropriate patient population. We do know that PARP is highly expressed in small cell lung cancer and large cell neuroendocrine carcinoma tumors. And thus, PARP inhibition has been one of the promising novel agents to use. However, we also know that Schlafen-11 is a predictive biomarker. It has been shown by Dr. Byers and colleagues that PARP inhibitors have been noted to have improved outcome in patients with Schlafen-11 positive patients. Also, Talazoparib has been noted to be one of the most potent PARP inhibitors. We designed our study to enroll patients with Schlafen-11 positive small cell lung cancer in order that they can receive the standard of care induction therapy with platinum etoposide Atezolizumab. However, when it comes to the maintenance part, they were randomized into arm A where they would receive standard of care Atezolizumab versus Atezolizumab plus Talazoparib, which is a PARP inhibitor. Reason is because we wanted to utilize that the PARP inhibitors are going to act very well in patients with Schlafen-11 positive status, and also because they do have a synergism to immunotherapies like PD-L1 inhibitors like Atezolizumab. That was the concept of the study and the design, with the main primary objective of progression-free survival. The study actually achieved its primary endpoint, and primary objective was met, where patients with Schlafen-11 positive small cell lung cancer when treated with atezolizumab and Talazoparib, they had a median progression-free survival of 4.2 months compared to 2.8 months of patients on the control arm. Having said that, we mentioned that it is still a small study. It's a phase two study. This is a good signal into a predictive biomarker based therapy. But in addition, also, the feasibility of having a biomarker in small cell lung cancer is very, very promising. There were only seven days median time to obtain the results of Schlafen-11, which is very reasonable for patients to select their maintenance therapy. Having said that, also, I want to mention that we are going to work into the levels of Schlafen-11, where they have high expression or lower expression, in correlation with the clinical outcome. That's the next step. Another follow up part is that this study actually starts the wave of new concepts where we can design studies in small cell lung cancer towards personalized approach rather than all comers, which of course was very useful to see in non-small cell lung cancer. If we can implement this in small cell lung cancer and get even more predictive biomarkers with basically Schlafen-11, but also with the subtypes of small cell lung cancer, and other markers, we also heard about in our ASCO 2023, like Dll3 and so on. If we can combine all those efforts together as the next step, this will be one of the best next movements.

Related Videos

CNS Cancers

Lisa M. DeAngelis, MD, and Ingo K. Mellinghoff, MD, on Glioma: Phase III Results on Vorasidenib

Lisa M. DeAngelis, MD, and Ingo K. Mellinghoff, MD, both of Memorial Sloan Kettering Cancer Center, discuss findings from the INDIGO trial showing that the IDH1/2 inhibitor vorasidenib improves progression-free survival for patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. These data demonstrate the clinical benefit of vorasidenib in this patient population for whom chemotherapy and radiotherapy are being delayed.

Skin Cancer
Immunotherapy

Jason J. Luke, MD, on Melanoma Adjuvant Therapy: Final Analysis of KEYNOTE-716

Jason J. Luke, MD, of the University of Pittsburgh Medical Center Hillman Cancer Center, discusses adjuvant pembrolizumab, which, in previous results, improved distant metastasis– and recurrence-free survival in patients with resected stage IIB or IIC melanoma vs placebo. After a median follow-up of 39.4 months, adjuvant pembrolizumab continued to show a benefit over placebo, with no new safety signals (Abstract LBA9505).

Leukemia
COVID-19

Jennifer A. Woyach, MD, on New Findings on CLL, COVID-19, and Treatment With Obinutuzumab Plus Venetoclax

Jennifer A. Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses results of a phase III study showing that progression-free survival with ibrutinib plus obinutuzumab plus venetoclax is not superior to ibrutinib plus obinutuzumab for treatment-naive older patients with chronic lymphocytic leukemia (CLL) in the setting of the COVID-19 pandemic. Long-term follow-up will determine whether there are advantages to obinutuzumab plus venetoclax, with special attention to measurable residual disease and therapy discontinuation (Abstract 7500).

Ajay K. Nooka, MBBS, Relapsed or Refractory Multiple Myeloma: Efficacy and Safety Data for Elranatamab

Ajay K. Nooka, MBBS, of Winship Cancer Center of Emory University, discusses findings from a pooled analysis of MagnetisMM studies. The data showed that, in patients with relapsed or refractory multiple myeloma who have not yet been treated with B-cell maturation antigen–directed therapies, elranatamab was efficacious and well tolerated.

Skin Cancer
Immunotherapy

Omid Hamid, MD, on Advanced Melanoma: Durable Response With Fianlimab Plus Cemiplimab

Omid Hamid, MD, of The Angeles Clinic & Research Institute, discusses study findings on fianlimab plus cemiplimab-rwlc, which showed clinical activity in patients with advanced melanoma, comparing favorably with other approved combinations of immune checkpoint inhibitors in the same clinical setting. This is the first indication that dual LAG-3 blockade may produce a high level of activity with significant overall response rate after adjuvant anti–PD-1 treatment. A phase III trial of this regimen in treatment-naive patients with advanced melanoma is ongoing (Abstract 9501).

Advertisement

Advertisement




Advertisement